Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins

Abstract

The present invention relates to recombinant DNA molecules which encode bovine respiratory syncytial (BRS) virus proteins, to BRS viral proteins, and peptides and to recombinant BRS virus vaccines produced therefrom. It is based, in part, on the cloning of substantially full length cDNAs which encode the entire BRS virus G, F, and N proteins. According to particular embodiments of the invention, DNA encoding a BRS virus protein or peptide may be used to diagnose BRS virus infection, or, alternatively, may be inserted into an expression vector, including, but not limited to, vaccinia virus as well as bacterial, yeast, insect, or other vertebrate vectors. These expression vectors may be utilized to produce the BRS virus protein or peptide in quantity; the resulting substantially pure viral peptide or protein may be incorporated into subunit vaccine formulations or may be used to generate monoclonal or polyclonal antibodies which may be utilized in diagnosis of BRS virus infection or passive immunization. In additional embodiments, BRS virus protein sequence provided by the invention may be used to produce synthetic peptides or proteins which may be utilized in subunit vaccines, or polyclonal or monoclonal antibody production. Alternatively a nonpathogenic expression vector containing the genes, parts of the genes, any combination of the genes, or parts thereof may itself be utilized as a recombinant virus vaccine.

1 . A vaccine composition comprising a suitable pharmaceutical vehicle and a recombinant infectious nonpathogenic virus which comprises an isolated nucleotide sequence, said isolated sequence comprising a coding sequence for an immunogenic bovine respiratory syncytial virus (BRSV) protein wherein said protein is selected from the group consisting of BRSV G, BRSV F, BRSV N and immunogenic fragments of BRSV G, BRSV F and BRSV N.  
     
     
         2 . A method of treating or preventing bovine respiratory syncytial virus infection in a bovine subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to  claim 1.